
GSK Awarded $63 Million US Government Contract for Pandemic Vaccine Research
GlaxoSmithKline (London, UK, www.gsk.com) has been awarded a $63.3-million contract from the US Department of Health and Human Services (HHS) for the development of pre-pandemic and pandemic flu vaccines.
GlaxoSmithKline (London, UK,
Under the terms of the contract, GSK will engage in research and development leading to licensure of antigen-sparing pre-pandemic and pandemic vaccines with adjuvant that will help the US government extend the limited North American supply of pandemic flu vaccines to protect larger populations in the event of a flu pandemic. The five-year contract also gives the government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.